Serum Phenylacetylglutamine Is a Potential Risk Factor for Aortic Stiffness in Patients with Chronic Hemodialysis
I-Min Su, Tsung-Jui Wu, Chin-Hung Liu, Yu-Li Lin, Bang-Gee Hsu · 2025
Read Serum Phenylacetylglutamine Is a Potential Risk Factor for Aortic Stiffness in Patients with Chronic Hemodialysis by I-Min Su, Tsung-Jui Wu, Chin-Hung Liu, Yu-Li Lin, Bang-Gee Hsu (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12731621.txt.
Description
I-Min Su and four co-authors test whether a gut-made chemical in the blood flags stiff arteries in dialysis patients, in a research paper from 2025. The chemical is called PAG, and it has been linked to heart and metabolism problems. Aortic stiffness is a known risk marker in people on long-term dialysis.
The study covered one hundred thirty-eight patients. About a third had aortic stiffness. Those patients were older and had higher blood pressure, blood sugar, and PAG levels. After accounting for other factors, PAG and age each predicted stiffness on their own. The authors say PAG could help spot dialysis patients at higher heart risk.
Catalog record
| CREATOR | I-Min Su, Tsung-Jui Wu, Chin-Hung Liu, Yu-Li Lin, Bang-Gee Hsu |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 21 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |